Latest News
News
Recruitment completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID
News
Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board
News
Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
News
Berlin Cures advances fight against Long COVID on a pan-European level
News
Berlin Cures takes next step in battle against Long COVID. Collaboration with Uniklinikum Erlangen as 5th German research center.
News
Berlin Cures starts Long COVID Phase II Trial – first patients admitted. Dr. Axel Mescheder appointed Chief Medical Officer.
News
Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth.
News
Heart Failure Treatment from Berlin Cures Shows Promise in Phase I Study.
News
BC 007 was successfully used for the treatment of a Long Covid Patient.
News
Functional autoantibodies against G protein-coupled receptors in patients with persistent Long-COVID-19 symptoms.
News
A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007.
News
The DNA-Based Drug BC 007 neutralizes agonistically acting autoantibodies directed against G protein-coupled receptors.
News
Berlin Cures’ Steering Committee is Assembled to Facilitate the Design and Implementation of Phase II Study of BC 007.
News
Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy.
News
Berlin Cures Announces Formation of Scientific Advisory Board.
Media Coverage